Skip to content

NSDQ: TPIV

$ ()

Phase 1 Whitepaper - TPIV200

TapImmuneTapImmune
TapImmune
An immuno-oncology company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease.
  • About
    • Overview
    • Our Story
    • Corporate Vision
    • Company Management
  • Technology
    • Overview
    • Pipeline
    • Clinical
    • Pre-Clinical
    • Patents
  • Collaborations
  • Investors
    • Overview
    • Investor Briefcase
    • Email Alerts
    • Stock Info
    • Financial Filings
    • FAQ
  • News
    • Overview
    • Press Releases
    • Events
    • Media Coverage
    • Press Kit / Media
  • Contact
  • About
    • Overview
    • Our Story
    • Corporate Vision
    • Company Management
  • Technology
    • Overview
    • Pipeline
    • Clinical
    • Pre-Clinical
    • Patents
  • Collaborations
  • Investors
    • Overview
    • Investor Briefcase
    • Email Alerts
    • Stock Info
    • Financial Filings
    • FAQ
  • News
    • Overview
    • Press Releases
    • Events
    • Media Coverage
    • Press Kit / Media
  • Contact

Daily Archives: January 3, 2018

You are here:
  1. Home
  2. 2018
  3. January
  4. 03

TapImmune to Present at Biotech Showcase™ 2018

Featured, Press ReleasesBy Aaron SantosJanuary 3, 2018

TapImmune President & CEO, Peter Hoang, to present at Biotech Showcase next week.

Sign up for email alerts

Get our news delivered to your inbox

Sign Up Today

Join the TPIV VIP List

Don't miss out. Get our news delivered to your inbox.

Join the TPIV VIP List